#News: Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 Read the full press release here: rb.gy/gpk4av

Yuanyuan leads clinical pharm. for our trials, ensuring optimal dosing & helping to advance our PROTAC® platform. Outside of work, she enjoys watching her son play basketball, reading, & watching movies. Learn more about members of #TeamArvinas: rb.gy/lhp36x

#News: Today we appointed Andrew Saik as Chief Financial Officer & Treasurer. Read our full press release here: rb.gy/9ajwk1

Excited to share that the most read article in ACS Publications Journal of Medicinal Chemistry for 2023 was authored by #TeamArvinas colleagues Keith Hornberger and Erika Vieira Araujo. Check it out! rb.gy/elos59 #MedicinalChemistry

Happy #4thOfJuly from #TeamArvinas. At Arvinas, we're celebrating the freedom to innovate & pursue groundbreaking treatments. We hope you and your family enjoy a safe holiday!

#DYK our founder Dr. @craigmcrews co-authored the 1st paper on targeted protein degradation over 20 years ago? We're excited to launch the #ScienceOfPROTAC series to celebrate our 11-year anniversary! Got questions about PROTAC protein degraders? Reply below! #Innovation

Mike ensures our Med. Affairs team operates efficiently & seamlessly. With 12+ years in the industry, he's dedicated to helping the company transition between clinical development and potential future commercialization. Learn more about #TeamArvinas: rb.gy/lhp36x

#TeamArvinas is honored to accept the award for Bioscience Company of the Year at the 22nd Annual Health Care & Life Sciences Awards! Thx Greater New Haven Chamber of Commerce for this award & your support!

Every summer we look forward to our annual #TeamArvinas picnic where we celebrate our accomplishments. Although we take our work seriously, we have fun too! Thx to our employees & interns for making this event so special & happy #NationalInternDay to our amazing interns!

Grateful to Greater New Haven Chamber of Commerce and @YNHHealth for naming us Bioscience Company of the Year! Our CEO, John Houston proudly accepted on behalf of our dedicated team. Thank you for this incredible #recognition! #Awards #TeamArvinas

#NEWS: Today Arvinas ($ARVN) shared Q2 financial earnings and a business update. Read the release here: rb.gy/bpooti #investors #biotechnews

Exciting insights from #Arvinas own Randy Teel on the future of protein degradation! Discover more about our path to leveraging #targetedproteindegradation to become leaders in the field. Listen to the full interview w/Daniel S. Levine to learn more. #TeamArvinas #Innovation Levine Media Group

This month’s #ScienceOfPROTAC focus is about the body’s primary mechanism for protein degradation: the ubiquitin-proteasome system. See how our #PROTAC technology can harness this system to destroy disease-causing proteins: bit.ly/3Sy8NKz

In a new vlog post, Chairperson, CEO & President John Houston chats w/ Pres. R&D Ian Taylor to discuss Ian's career journey, lessons learned & his secrets to staying motivated. Check it out: rb.gy/kgoi4p #Motivation #ProfessionalGrowth

On #BreastCancerResearchDay we celebrate the incredible progress that has been made in #breastcancer research and recognize the need for new advancements. #TeamArvinas is committed to investigating treatment options for breast cancer to improve the lives of patients.

Part of Eileen’s role involves connecting w/ HCPs & researchers to understand patient needs & preferences. This helps inform our clinical trial designs & research. Her background as an oncology nurse strengthens her connection to our mission. #TeamArvinas #MeetTeamArvinas

At #Arvinas, we are continuously enhancing our degrader discovery engine. We’ve competed our first fully automated High Throughput Screen w/ the @ThermoFisher Robot, UbiQTron, to identify new degrader chemical matter for important disease modifying targets. #ProteinDegradation

We welcomed Rebecca Surran from News12CT to #Arvinas for an exclusive look at our labs! She joined CSO Angela Cacace to discuss our innovative research & commitment to developing new treatments for life-altering diseases. Check it out: rb.gy/r9t4qo #TeamArvinas #TPD

🩸There are many types of #bloodcancer – each w/ different symptoms, treatments, & prognoses. We're focused on raising awareness & researching treatments for non-Hodgkin Lymphoma. Join us and turn September red for #BloodCancerAwarenssMonth. Get involved: bit.ly/47aC8Rm

#TeamArvinas is singularly focused on developing a new class of medicines that aim to be transformative for patients and their HCPs. Our #ScienceOfPROTAC approach is to challenge the limits of drug discovery. Learn more: bit.ly/3VsygaB